- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07726654
The Longitudinal Cohort of Cerebral Small Vessel Disease in Ruijin Hospital
The goal of this observational study is to learn about neuroimage and biomarkers in the cerebral small vessel disease. The main questions it aims to answer are:
- How does neurovascular coupling change during the progression of CSVD?
- How is the pattern/mapping of alterations in CSVD biomarkers? Participants will be observed and visit the research center annually to perform multi-modal MRI, PET, neuropsychological tests, and blood tests.
Przegląd badań
Status
Warunki
Szczegółowy opis
This observational study recruits participants with cerebral small vessel disease (CSVD) from hospitals and community-based populations. Healthy volunteers will also be recruited as controls. Longitudinal follow-up of these participants will help clarify the significance of neuroimaging and biological biomarkers during the development and progression of CSVD.
The investigators aim to establish a longitudinal cohort covering the spectrum of CSVD and identify key biomarkers associated with disease progression and cognitive decline. All participants will undergo multimodal MRI, PET imaging (optional) with different tracers, and blood biomarker assessments. Using multimodal MRI, the investigators will investigate alterations in neurovascular coupling and their role in the pathophysiology of CSVD. In addition, PET imaging (optional) and blood biomarkers will be used to characterize the spatial and temporal patterns of disease-related biomarker changes. Furthermore, additional neuroimaging and digital biomarkers will be evaluated within the cohort to improve disease characterization and prognostic prediction.
Typ studiów
Zapisy (Szacowany)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chiny, 200025
- Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
-
Kontakt:
- Jingyan Tian, Dr
- Numer telefonu: 13671865057
- E-mail: tjy11488@rjh.com.cn
-
Główny śledczy:
- Jingwen Jiang, Dr.
-
Pod-śledczy:
- Binyin Li, Dr.
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- Age ≥18 years.
Evidence of cerebral small vessel disease (CSVD) on brain MRI, meeting at least one of the following imaging criteria:
- White matter hyperintensities (WMH) with a total Fazekas score ≥2;
- Fazekas score =1 with at least two vascular risk factors (hypertension, hyperlipidemia, diabetes mellitus, obesity, current smoking, or a history of vascular events other than stroke);
- Fazekas score =1 accompanied by the presence of lacunes;
- Imaging evidence of a recent subcortical lacunar infarction.
- Independent in activities of daily living (modified Rankin Scale [mRS] ≤2).
- Able and willing to provide written informed consent.
Exclusion Criteria:
- Acute ischemic stroke with a diffusion-weighted imaging (DWI) lesion >20 mm in diameter.
- Acute intracerebral hemorrhage.
- Acute subarachnoid hemorrhage, a history of aneurysmal subarachnoid hemorrhage or cerebrovascular malformation, or the presence of an untreated intracranial aneurysm >3 mm in diameter.
- Previously diagnosed neurodegenerative disorders, such as Alzheimer's disease (AD) or Parkinson's disease (PD).
- Definite non-vascular white matter diseases, including multiple sclerosis, adult-onset leukodystrophy, metabolic encephalopathy, or other non-vascular white matter disorders.
- Major psychiatric disorders diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
- Contraindications to MRI (e.g., severe claustrophobia or MRI-incompatible implants).
- Severe systemic diseases (e.g., active malignancy) with an expected life expectancy of less than 5 years.
- Inability to complete scheduled follow-up because of geographic, logistical, or other reasons.
- Concurrent participation in another interventional clinical trial.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
|---|
|
Cognitively Normal
Participants do not have cognitive impairment.
|
|
Cerebral small vessel disease without dementia
Participants have vascular cognitive impairment, but no cognitive impairment
|
|
Vascular Dementia (VaD)
Participants have vascular cognitive impairment or difficulty in daily activity.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Global cognitive ability
Ramy czasowe: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Mini-mental state examination
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Executive function
Ramy czasowe: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Clock drawing test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Visual memory
Ramy czasowe: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Rey-Osterich complex figure test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Short-term memory
Ramy czasowe: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Auditory verbal learning test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Executive memory
Ramy czasowe: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Symbol-digit test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Spatial executive function
Ramy czasowe: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Trail making test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Naming ability
Ramy czasowe: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Boston naming test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Language ability
Ramy czasowe: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Language fluency test
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Sleep quality
Ramy czasowe: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Sleep disorder
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Movement ability
Ramy czasowe: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Part III of the Unified Parkinson's Disease Rating Scale
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Brain volume
Ramy czasowe: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Annual changes of volumes of brain
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Connectivity integrity of the neural circuit
Ramy czasowe: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Annual changes of hippocampus related neural connectivity
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
|
Volume of white matter lesions
Ramy czasowe: baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Structural and functional MRI measures, including arterial spin labeling (ASL), diffusion MRI (dMRI), susceptibility-weighted imaging (SWI) and fluid-attenuated inversion recovery (FLAIR).
|
baseline, 1 year, 2-year, 3-year, 5-year,10-year
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- RJNeuroBank-SVD
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .